Need a new search?

Agendia’s Microarray-based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II Colon Cancer Patients IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 1, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint Read More

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – There are substantial differences between the results provided by Agendia’s next-generation breast cancer tests and more limited results from the first-generation, 21-gene assay, according to findings presented at the recently concluded annual meeting of the American Society Read More

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New research involving Agendia’s genomic tests MammaPrint®, BluePrint®, TargetPrint® and TheraPrint®, as well as its ColoPrint® Colon Cancer Genomic Profile, will be reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO), May 30 Read More

CHICAGO – Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO). This scientific poster was one chosen for discussion at the ASCO conference due to the Read More

IRVINE, CA, May 31, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June Read More

Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 29, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, “Present and Future Trends in Breast Cancer Genomics,” on Saturday, August 25, 2012. The event was held Read More

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 9, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Stefan Glück, MD, PhD, will lead the company’s Medical Advisory Board. As Chairman, Dr. Glück is assembling a panel of leading medical Read More

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, July 10, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Dr. Mark Gittleman, Medical Director of Breast Care Specialists and Advanced Breast Care Imaging, has joined the company’s Medical Advisory Board. The Read More

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, July 9, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Vice President of Finance. “It is a Read More